Shlomo Melmed, MB, ChB, the first recipient of the Transatlantic Alliance Award from the Endocrine Society and the European Society of Endocrinology (ESE) will be a featured speaker at ENDO 2022.
Melmed’s talk, “Growth Hormone: An Adult Endocrine Misnomer,” will be featured in the Presidential Plenary, “Health Equity in Endocrinology” beginning at 2 p.m. on Saturday June 11, in Hall A3 at the Georgia World Conference Center. Melmed is scheduled to speak from 3:00 PM to 3:30 PM in what promises to be a very informative and intriguing session.
As we first announced in September 2021, this inaugural joint award recognizes an international leader who has made significant advancements in endocrine research in Europe and the U.S. Melmed was chosen for his pioneering research in pituitary medicine and endocrine tumors.
Melmed, executive vice president of Academic Affairs and dean of the Medical Faculty at Cedars-Sinai, Los Angeles, Calif., has pioneered the discovery and application of novel treatments for endocrine tumors. In his National Institutes of Health-funded laboratory, he investigates molecular mechanisms and new treatments for pituitary tumors and related hormonal disorders.
“I am truly humbled to be chosen as the inaugural recipient of this international award,” Melmed says. “For me, this award celebrates all of our Cedars-Sinai physicians and scientists who are working tirelessly to find better ways to treat debilitating chronic diseases.”
Melmed, who also holds the Helene A. and Philip E. Hixon Distinguished Chair in Investigative Medicine at Cedars-Sinai, has authored more than 350 articles in prestigious peer-reviewed journals. These journal articles include a recent paper in Cell Reports that provides important clues on how local non-pituitary growth hormone is activated in aging colon tissue and initiates the first steps in tumor development.
As a gifted educator, Melmed has also trained more than 80 physicians, scientists and graduate students. He plays a major role in leading the growth of research and educational programs at Cedars-Sinai, which is now one of the nation’s top-tier non-university academic medical centers.
“Dr. Melmed’s distinguished career has set a high bar for endocrine researchers on both sides of the Atlantic,” says Endocrine Society President Carol Wysham, MD, clinical professor of medicine at the University of Washington in a press release. “We and our partners at ESE are proud to be recognizing a worldwide leader who is advancing our field.”
Melmed will give a plenary address, “Growth Hormone: An Adult Endocrine Misnomer,” at the forthcoming European Society of Endocrinology’s 24th European Congress of Endocrinology in Milan, Italy.